2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116463
    E1R 1301211-78-8 99.83%
    E1R is a positive allosteric modulator of sigma-1 receptors (Sig1R PAM) with cognition-enhancing activity.
    E1R
  • HY-116480
    LY593093 1108748-12-4 98%
    LY593093 is a selective, orally active, and brain-penetrant muscarinic M1 receptor agonist with an EC50 of 22.8 nM. LY593093 can be utilized in Alzheimer’s disease research.
    LY593093
  • HY-116561
    Adamantylmethamphetamine hydrochloride 19835-42-8 ≥98.0%
    Adamantylmethamphetamine hydrochloride is a psychotic compound, possessing a central action. Adamantylmethamphetamine hydrochloride has effects on hexobarbital sleeping time, spontaneous motor activity, and the potentiation of metrazole and antifatigue activity.
    Adamantylmethamphetamine hydrochloride
  • HY-117408
    VU6004256 2011034-33-4 99.61%
    VU6004256 is a potent and selective M1 muscarinic positive allosteric modulator (PAM) with an EC50 value of 155 nM. VU6004256 has the potential for the research of schizophrenia.
    VU6004256
  • HY-117547
    Licostinel 153504-81-5 98.12%
    Licostinel (ACEA-1021) is a glycine receptor antagonist (IC50: 59 nM). Licostinel has neuroprotective activity.
    Licostinel
  • HY-117604
    THPP-1 1257051-63-0 98.75%
    THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.
    THPP-1
  • HY-118140
    ZCZ011 1998197-39-9 ≥99.0%
    ZCZ011 is a potent and brain penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain.
    ZCZ011
  • HY-118158
    FAAH/MAGL-IN-4 256383-45-6 99.83%
    FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC50s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders.
    FAAH/MAGL-IN-4
  • HY-118538
    Noreximide 3647-74-3
    Noreximide is a sedative, and can be used for psychiatric disease research.
    Noreximide
  • HY-118796
    4-Hydroxy MET 77872-41-4 99.20%
    4-Hydroxy MET (4-HO-MET) is a psychoactive tryptamine (NPS), a structural variant of the endogenous neurotransmitter serotonin. 4-Hydroxy MET has hallucinogenic effects, affecting mood, movement, and cognitive function.
    4-Hydroxy MET
  • HY-119078
    VU0080241 393845-24-4 99.69%
    VU0080241 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 4 (mGluR4), with an EC50 of 4.6 μM.
    VU0080241
  • HY-119097
    LY456066 338738-66-2 ≥99.0%
    LY456066 is a selective non-competitive metabotropic glutamate receptors (mGluR1) antagonist with an IC50 value of 52.0 nM. LY456066 is effective in rodent models of anxiolysis and nociception. LY456066 reduces hyperalgesia and the amount of licking and flinching following formalin injection, which is promising for research of analgesics for chronic pain.
    LY456066
  • HY-119173
    PBD-150 790663-33-1 99.53%
    PBD-150 is a human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a Ki value of 490 nM.
    PBD-150
  • HY-119282
    AZD6538 453566-30-8 98%
    AZD6538 is a potent, selective and brain penetrant mGluR5 negative allosteric modulator. AZD6538 inhibits DHPG (HY-12598A)-stimulated intracellular Ca2+ release in HEK cells expressing rat or human mGluR5, with IC50 values of 3.2 and 13.4 nM for rat mGluR5 and human mGluR5, respectively. AZD6538 can be used for the research of neuropathic pain.
    AZD6538
  • HY-119910
    (E)-Aminoquinol 529507-84-4 99.70%
    (E)-Aminoquinol (XIB4035) is a GFRα-1 agonist. (E)-Aminoquinol has mimic neurotrophic effects of GDNF, and induces Ret autophosphorylation in Neuro-2A cells. (E)-Aminoquinol can be used for research of Parkinson’s disease.
    (E)-Aminoquinol
  • HY-120475
    PBT434 1232841-78-9 98.86%
    PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD).
    PBT434
  • HY-120566
    PSB-16131 1213268-80-4 99.94%
    PSB-16131 is a potent inhibitor of human NTPDase2, showing non-competitive inhibition with an IC50 of 539 nM. PSB-16131 can be used in the study of inflammation, neurodegenerative diseases and cancer.
    PSB-16131
  • HY-120692
    Cyclanoline chloride 17472-50-3
    Cyclanoline (chloride) shows cholinesterase inhibitory activity.
    Cyclanoline chloride
  • HY-120751
    TROX-1 1309601-26-0 98%
    TROX-1 is an N-type calcium channel (CaV2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 can be used in chronic pain research.
    TROX-1
  • HY-120949
    (1R,2R)-U-50488 hydrochloride 109620-49-7 ≥98.0%
    (1R,2R)-U-50488 hydrochloride is the absolute stereochemistry of (±)-U-50488 hydrochloride. (±)-U-50488 hydrochloride is a selective κ opioid receptor (KOR) agonist.
    (1R,2R)-U-50488 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity